Compare · ABBV vs BRVE

ABBV vs BRVE

Side-by-side comparison of AbbVie Inc. (ABBV) and Braveheart Bio Inc. (BRVE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ABBV and BRVE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • ABBV is the larger of the two at $505.56B, about 303.6x BRVE ($1.67B).
  • ABBV has been more active in the news (16 items in the past 4 weeks vs 10 for BRVE).
  • ABBV has more recent analyst coverage (25 ratings vs 0 for BRVE).
MetricABBVBRVE
Company
AbbVie Inc.
Braveheart Bio Inc.
Price
-
-
Market cap
$505.56B
$1.67B
1M return
-1.02%
-
1Y return
+22.83%
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2012
2026
News (4w)
16
10
Recent ratings
25
0
ABBV

AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.

BRVE

Braveheart Bio Inc.

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy ('HCM') and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor, that we are developing for the treatment of obstructive HCM and non-obstructive HCM. Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity. BHB-1893 was initially discovered and developed by Jiangsu Hengrui Pharmaceuticals Co in China. We in-licensed BHB-1893 pursuant to an exclusive license agreement with Hengrui.

Latest ABBV

Latest BRVE